immatics, a biopharmaceutical company that specializes in the development of peptide-based immunotherapeutic substances for the treatment of cancers, today announced the successful conclusion of its first Phase 1 clinical study on vaccine IMA901 against renal cell cancer. IMA901 is a combination of 10 different peptide antigens that can be identified as so-called tumor-associated antigens among the majority of renal cell cancer patients.
